Alvotech
NASDAQ: ALVO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Lisa Graver
- Employees
- 1,012
- Headquarters
- Luxembourg, Iceland
- IPO year
- 2022
- Market cap
- $1.2B
- Website
- https://www.alvotech.com
Loading ALVO…
Loading profile data…Frequently asked questions about ALVO
What does Alvotech (ALVO) do?
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar eq...
Where does ALVO trade?
Alvotech (ALVO) trades on the NASDAQ Global Market.
What sector is ALVO in?
Alvotech (ALVO) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Alvotech?
Lisa Graver is the chief executive officer of Alvotech (ALVO).
Where is Alvotech headquartered?
Alvotech is headquartered in Iceland.
Does ALVO pay a dividend?
Alvotech (ALVO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALVO go public?
Alvotech (ALVO) completed its initial public offering in 2022.